Building on its expertise in anti-inflammatory drug discovery, the company has designed and produced a series of compounds that have the potential to be beneficial in the treatment of serious eye diseases, including those that affect the back of the eye, through delivery to the retina by an eye drop.
Inflammatory eye diseases may result in damage of eye tissue, leading to reduced vision and/or vision loss.
Designing small molecules that block pro-inflammatory mediators in disease.
Cras porttitor nisl leo, in vestibulum mauris hendrerit vel. Nam sit amet accumsan neque.
Chronic inflammatory disease represents an enormous societal and economic burden, particularly in an aging population, impacting both quality and quantity of life. Naegis Pharmaceuticals Inc. is driven to discover new therapies that target underlying chronic inflammatory processes in disease. The Naegis research team seeks to design new drugs that offer safer and more effective treatment options for patients, focusing first on serious eye conditions that result in damage to the back of the eye, with a program directed towards blocking the synthesis of pro-inflammatory mediators in disease. [...]